EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma

Phase 1 Terminated 30 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of EMD 121974 in treating patients who have HIV-related Kaposi's sarcoma. EMD 121974 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.

Timeline

Start: 2000-09
Primary completion: 2001-03
Completion: 2001-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	cilengitide	Peptide	—	Intravenous

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma

Summary

Timeline

Drugs

Indications